Cargando…

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Zeng, Zhihong, Konopleva, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849332/ https://www.ncbi.nlm.nih.gov/pubmed/33522781 http://dx.doi.org/10.3324/haematol.2020.266809

Ejemplares similares

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
por: Chen, Chong, et al.
Publicado: (2013)

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
por: Gruber, Emily, et al.
Publicado: (2023)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

IDH1/2 mutations in acute myeloid leukemia
por: Byun, Ja Min, et al.
Publicado: (2022)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020)

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
por: Yuile, Alexander, et al.
Publicado: (2022)

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
por: Koncar, Robert F., et al.
Publicado: (2017)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
por: Sarkaria, Shawn M., et al.
Publicado: (2014)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_95lf5eer77smd22kd4jv0pgvap